Oct 2, 2006 (CIDRAP News) – In a major push to modernize and speed the production of vaccines for pandemic influenza and other emerging threats, the US Food and Drug Administration (FDA) last week issued new guidance on how to safely and effectively develop new cell-based vaccines.The document, released Sep 28, updates 13-year-old guidelines on cell culture manufacturing, currently used to make vaccines for other diseases such as measles, mumps, and polio, according to an FDA press release.The currently used egg-based method of producing influenza vaccines hasn’t changed much in 50 years and is more laborious than cell culture production techniques. To produce a vaccine, the virus strain must be adapted to grow in eggs, and huge quantities of special fertilized eggs must be available.With cell culture technology, manufacturers grow vaccine components in human or animal cells so the viruses don’t need to be adapted. Cells can be frozen and stored for use when needed, allowing production to be quickly ramped up in the event of an emergency.”The advice will assist manufacturers, including those that make influenza vaccine, both to develop new and better vaccines and to boost production capacity, making us better prepared for the threat of a future influenza pandemic and other infectious diseases,” said Jesse Goodman, MD, MPH, in the press release. Goodman directs the FDA Center for Biologics Evaluation and Research.The guidance helps vaccine makers determine the suitability of a cell culture for manufacturing, as well as test and validate the safety and purity of the cells. The document also advises when to test at different stages of production and defines quality-control testing methods for cell substrate and adventitious agents.The US Department of Health and Human Services (HHS) has made cell-based vaccine manufacturing a central focus of its pandemic plan. In May it awarded $1 billion among five companies to develop cell-based technologies for making flu vaccines.In April 2005, HHS awarded Sanofi Pasteur a $97 million contract to develop a cell-based flu vaccine. The company was the first to receive a federal contract for commercial-scale use of new flu vaccine technology.Last week, Sanofi Pasteur announced the launch of the first clinical trial of its first seasonal influenza vaccine made using cell culture technology.See also: May 4 CIDRAP News article “US awards $1 billion for cell-based flu vaccines”Jun 27, 2005, CIDRAP News article “Momentum builds for cell-culture flu vaccines”
These trips will begin on September 8 with three daily flights from the Seasonal Trips Building at the Cairo Airport, he added.The agreement is not the first of its kind, as the company has always been keen on providing travel services to Palestinian people and ease their suffering, Nahas said.He stressed that EgyptAir will facilitate the procedures of the trips in coordination with Cairo Airport authorities. The head of EgyptAir, Hesham al-Nahas, said Wednesday that the airline company has signed a cooperation agreement with Palestinian Airways, under which the company will operate nine charter flights to transport 2,200 Palestinian pilgrims to Mecca and Medina in Saudi Arabia this year.
For all the Latest Sports News News, Cricket News News, Download News Nation Android and iOS Mobile Apps. New Delhi: India’s star batter Mithali Raj announced retirement from T20 Internationals on Tuesday. Mithali still continues to captain Indian women cricket team in the ODI internationals. Mithali Raj, who started her international career in 1999 is one of the most successful woman cricketers. She has captained India in 32 T20I games which also includes three world cup tournaments.“Former India T20I captain, Ms Mithali Raj has announced her retirement from T20 Internationals. Mithali led India in 32 T20Is including the three Women’s WT20 World Cups in 2012 (Sri Lanka), 2014 (Bangladesh) and 2016 (India)”, reads BCCI press release confirming Mithali’s retirement from T20 internationals. She has played 89 T20Is for India in which she scored 2,364 runs with an average of 37.52. She has hit 17 test fifties. She played her last T20 international against England in Guwahati. She scored an unbeaten 32 off 30 balls in that match. As she bids adieu to the shortest format of the game, she finishes as the sixth highest run getter, behind the likes of Suzie Bates, Charlotte Edwards and others. Mithali Raj announced retirement from T20 InternationalsShe is one of the most successful woman cricketersShe has played 89 T20Is for India in which she scored 2,364 runs highlights